Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

This case report describes a 39-year-old woman whose dermatomyositis-systemic lupus erythematosus overlap syndrome symptoms resolved after switching to tofacitinib.

In this case study, a transition to the MEK inhibitor trametinib successfully stabilized disease and reduced toxicity in a patient with refractory kaposiform lymphangiomatosis after prolonged sirolimus and steroid treatment.

This study observed that a topical liposome formulation of a 5‐α‐reductase inhibitor effectively reduced the size of treated sebaceous glands and induced apoptosis in a hamster model, suggesting potential benefits for acne treatment.

This case report describes a Balinese breed dog diagnosed with demodecosis and malasseziosis, which improved after 30 days of treatment including amitraz, ketoconazole, and supportive therapies. The findings suggest that consistent treatment and environmental management can aid in recovery from these skin conditions in dogs.

This study found that MF patients with darker skin types show slower initial improvement with NB-UVB phototherapy, highlighting disparities in treatment efficacy that warrant further investigation.

This article reviews the increasing incidence of frontal fibrosing alopecia since its first description in 1994 and reports no new results.

This study demonstrates that a proposed multi-stage framework improves the accuracy and faithfulness of drug-related responses generated by language models, compared to traditional methods.

In this study, pregnant spotted hyenas treated with flutamide and finasteride had lower concentrations of several sex hormones, including testosterone and luteinizing hormone, compared to untreated controls.

This review discusses the enigmatic nature of frontal fibrosing alopecia and reports no clinical results; the authors stress the need for further research.

In this study, the PLP2 gene was found to promote secondary hair follicle development in Liaoning cashmere goats, with its expression negatively regulated by melatonin and potentially affecting follicle development via the BMP pathway.

This case report describes a woman with frontal fibrosing alopecia who did not improve with hydroxychloroquine and topical minoxidil but achieved clinical stabilization with methotrexate monotherapy.

This report diagnosed a 68-year-old man with comedonal folliculotropic mycosis fungoides based on clinical and histopathological findings, and found pegylated interferon alpha-2a with isotretinoin beneficial in reducing skin lesions.

This abstract does not report any research results but mentions researcher affiliations and potential conflicts of interest, indicating the researchers' involvement in various pharmaceutical collaborations.

This study found that FLCN deficiency in mice muscles led to increased mitochondrial biogenesis and a metabolic shift towards oxidative phosphorylation, with a similar advantage observed in FLCN-null kidney cancer cells.

Mycophenolic acid may help hair growth, a combination treatment improves hair thickness in male hair loss, and early treatment of frontal fibrosing alopecia is important.

In this study, frontal fibrosing alopecia showed a higher cumulative remission rate compared to lichen planopilaris, despite similar timeframes and relapse rates between the two conditions.

In this study, researchers found that FGF9 plays a significant role in sheep wool growth by accelerating the proliferation and cell cycle of dermal papilla cells, potentially through regulation of the Wnt/β-catenin signaling pathway.

This study found that tofacitinib may be effective for treating pediatric rheumatic diseases, with especially promising results in patients with autoinflammatory diseases, arthritis and alopecia, and juvenile dermatomyositis.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This study found that subcutaneous injections of basic fibroblast growth factor in neonatal mice delayed the development and hair growth cycles of hair follicles compared to controls.

In this study, FCO2 laser treatment showed significantly better improvement for alopecia areata compared to traditional intralesional corticosteroid injections, with no serious side effects or relapse observed.

This review highlights available treatments for frontal fibrosing alopecia, noting that 5-alpha reductase inhibitors, intralesional steroids, and hydroxychloroquine currently have the most evidence supporting their use, while other treatments show variable results and require further study.

In this case report, a 66-year-old woman with rheumatoid arthritis developed cutaneous ulceration attributed to leflunomide treatment, which significantly healed after discontinuing the drug and administering cholestyramine, underscoring the need for careful monitoring of leflunomide's adverse effects.

This case study reports successful treatment of frontal fibrosing alopecia with daily 2.5mg finasteride in a 77-year-old woman.

This article highlights the significant hair transplant results achieved with the potentially obsolete FUT technique and includes varied expert opinions on its efficacy, but it reports no new clinical findings.

In this case report, folliculitis decalvans with frontal fibrosing alopecia was observed in a patient with a dark phototype, highlighting the phenotypic spectrum of folliculitis decalvans and lichen planopilaris.

The researchers reported a case where treatment with tofacitinib improved both hair loss and skin lesions in a patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa over six months, with no recurrence or adverse events during two-year follow-up.

In this study, the choice between Belimumab and Anifrolumab for treating Systemic Lupus Erythematosus was mainly influenced by the clinical features of the disease, such as chronic-active or relapsing-remitting courses and specific manifestations like cutaneous involvement or arthritis.